Latest News & Features

Reset all filters
Article Type
Channels & Sectors
Geography
Company

Refine Search
Big Pharma
Biopharmaceutical company AbbVie’s pending purchase of pharmaceutical company Allergan has moved a step closer, following the latter’s agreement to divest treatments brazikumab and Zenpep, in a development meant to satisfy antitrust regulations in the US.   28 January 2020
Biotechnology
Arnold & Porter partner Richard Dickinson has joined Bristows as a partner in its commercial and IP transactional practice in London.   28 January 2020
article
Parker Poe Adams & Bernstein has announced the addition of five patent attorneys to its life sciences team.   28 January 2020
Americas
Gilead Sciences has accused a US government agency of withholding information from the US Patent and Trademark Office when filing two patents for HIV pre-exposure prophylaxis.   27 January 2020
Big Pharma
Secondary medical use case trends and research exemptions are just two issues set to be discussed at C5’s 12th Pharma & Biotech Patent Litigation meeting, on February 25–26 in Amsterdam.   27 January 2020
Americas
Jason Markwell, a former partner at Belmore Neidrauer, has joined Fasken’s IP group in its Toronto office.   24 January 2020
Big Pharma
The Court of Justice of the European Union has rejected two appeals that would have restricted the European Medicines Agency’s right to publish a pharmaceutical company’s clinical trial data, as it relates to their applications to market their products within the EU.   24 January 2020
Big Pharma
Molecular testing company Ascenda BioSciences is suing a former chief operations officer, claiming he attempted to “extort” the return of sensitive company information before taking up employment with a direct competitor.   23 January 2020
Americas
Washington State University is suing two apple producers who it says have infringed its patent through the unlicensed cultivation and sale of a proprietary apple variety.   23 January 2020
Big Pharma
GlaxoSmithKline may have restricted competition by making a deal with generic drugmakers to delay the launch of copies of an antidepressant, according to an adviser to the Court of Justice of the European Union.   23 January 2020